Enrico Zanardo
Education
Ph.D. and M.Phil., economics, Columbia University; M.S., applied mathematics, University of Padua; B.A., mathematics, University of Padua
Summary of Experience
Dr. Zanardo specializes in formalizing economic and statistical models designed to evaluate health outcomes, measure online advertisements’ effectiveness, and assess the merits of antitrust claims in high-tech and pharmaceutical markets. In his health economics work, Dr. Zanardo has modeled differences in health care resource utilization and costs between patient cohorts, designed surveys to collect patient outcomes from electronic medical records, and applied machine-learning algorithms to derive predictive models. In his litigation work, he has supported academic affiliates in projects that have involved measuring consumers’ willingness to pay for consumer goods, modeling the market for online display advertisements on social networks, and investigating the impact of Amazon reviews on online and offline sales. Dr. Zanardo has experience analyzing a wide variety of datasets, including medical and pharmacy claims datasets, Nielsen consumer goods scanner data from leading US retailers, Slice online sales data, proprietary internal profit and loss reports, and drug formulary placement.
- 
                                                        Treatment Patterns, Healthcare Resource Utilization, and Costs of Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the USThe Oncologist, 2024 
 2024Yang X, Zanardo E, Lejeune D, De Nigris E, Sarpong E, Farooqui M, Laliberté F 
- 
                                                        Impact of formulary-related pharmacy claim rejections of cariprazine on health care utilization and treatment patterns among patients with bipolar I disorderJournal of Managed Care & Specialty Pharmacy, 2024 
 2024Laliberté F, Zanardo E, MacKnight SD, Urosevic A, Wade SW, Parikh M 
- 
                                                        Healthcare resource utilization and costs of chronic lymphocytic leukemia/small lymphocytic lymphoma patients who relapse or are refractory to ibrutinibFuture Oncology, October 2024 
 2024De Nigris E, Yang X, Zanardo E, Lejeune D, Farooqui MZH, Gandra SR, Laliberté F 
- 
                                                        Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysisBMC Ophthalmology, 2023 
 2023Karpecki P, Barghout V, Schenkel B, Huynh L, Khanal A, Mitchell B, Yenikomshian M, Zanardo E, Matossian C 
- 
                                                    November 4, 2024
- 
                                                    December 1, 2023
- 
                                                    March 2, 2023
- 
                                                    December 7, 2022
